Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

GenScript Forms Bispecific Partnership with Korea's ABL Bio

publication date: Nov 18, 2019

GenScript Biologics, a Nanjing global biopharma CDMO, will partner with ABL Bio of South Korea to develop two bispecific antibodies using GenScript technology. GenScript will grant a sublicense to ABL Bio to use its sdAb (single-domain antibody), mAb (monoclonal antibody) targeting tumor antigens, and its Single-Domain Antibody fused to Monoclonal Ab (SMAB) Platform. In addition, GenScript will supply CDMO services to ABL for IND-enabling studies and clinical trial manufacturing of the immunotherapies. GenScript will receive upfront and milestone payments, plus royalties, though details were not provided. More details....

Stock Symbols: (HK: 1548) (KQ: 298380)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.